All In Biotech

Drug Trial Radar · NCT07623824

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly

A Randomized, Parallel, Open-label, Multicenter, Positive-controlled, Superiority Phase III Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

154

Planned (sponsor's estimate)

Start

May 31, 2026

Primary completion

Jul 31, 2029

Study completion Dec 30, 2029

Sponsor

Sponsor type
Industry
First posted
Jun 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.

Conditions

  • Diagnosed With Acromegaly, Currently in the Active Stage of the Disease

Interventions

  • SYHX2008Drug

    The patients will accept SYHX2008 injection by subcutaneous administration.A treatment period of 28 weeks.

  • Sandostatin LAR®Drug

    The patients will accept Sandostatin LAR@ by intra-muscular administration.A treatment period of 28 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with an IGF-1 index ≤ 1.0Time frame: Week 28

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.